1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Compliance

Compliance 360° Part 8: Patient Influence On US FDA’s Enforcement Strategy

 
• By Shawn M. Schmitt

This is Compliance 360°, a podcast series from Medtech Insight on US FDA compliance and enforcement issues. In this eighth installment, former FDA investigations branch director Ricki Chase explains how the role of the patient influences FDA's enforcement strategy and discusses the agency's recent industry guidance on benefit-risk factors.

MT1701_Compliance360
Other Compliance 360° Podcasts

Patients are playing an ever-increasing role in how US FDA approaches its compliance and enforcement priorities, former agency investigations branch director Ricki Chase says.

Indeed, FDA's Center for Devices and Radiological Health "has been increasingly interested in the patient experience and what role that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

Global Medtech Guidance Tracker: September 2025

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

Dexcom Pushes Forward With R&D Growth, New Devices Amid Scrutiny And Shake-Up

 
• By Marion Webb

Dexcom has endured recalls, layoffs and leadership change, but interim CEO Jake Leach said the company remains committed to innovating next-gen devices.

OIG Urges Reforms To Medicare Skin Substitute Payments

Expect fresh scrutiny on skin substitute payments as the Office of the Inspector General found Medicare reimbursement for the products has continued its rapid increase despite fraud and abuse concerns.

Pair Of Safety Alerts In Line With Broader FDA Enforcement Crackdown

 
• By Brian Bossetta

The US FDA issued two safety alerts concerning associated risks from unauthorized medical devices. The alerts are consistent with a larger effort to clamp down on consumer goods that have not been subject to agency review.

More from Policy & Regulation

Biolinq Aims To ‘Shine’ In Early 2026 With Needle-Free CGM US Debut, Human Data On Protein Sensor

 
• By Marion Webb

Fresh off de novo clearance, Biolinq plans to launch its needle-free CGM for type 2 diabetes not on insulin in early 2026. Pricing has not been disclosed, but “won’t be too far apart” over rivals Abbott’s Lingo and Dexcom’s Stelo CGMs, CEO Rich Yang said.

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By Elizabeth Orr

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.

FDA Wants Help In Figuring Out How AI-Enabled Devices Work In ‘The Real World’

 
• By Brian Bossetta

The US FDA is seeking public input on practical approaches to evaluating the performance of AI-enabled medical devices. The agency says it wants to build off insights gained from a public advisory committee last year that discussed how best to evaluate these devices once they are in use.